These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22174554)

  • 1. Thalidomide induces mucosal healing in Crohn's disease: case report.
    Leite MR; Santos SS; Lyra AC; Mota J; Santana GO
    World J Gastroenterol; 2011 Dec; 17(45):5028-31. PubMed ID: 22174554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
    Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
    J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
    Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.
    Srinivasan R; Akobeng AK
    Cochrane Database Syst Rev; 2009 Apr; (2):CD007350. PubMed ID: 19370684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.
    Ginsburg PM; Dassopoulos T; Ehrenpreis ED
    Ann Med; 2001 Nov; 33(8):516-25. PubMed ID: 11730158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy.
    Hershfield NB
    Can J Gastroenterol; 2004 Feb; 18(2):101-4. PubMed ID: 14997219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
    Plamondon S; Ng SC; Kamm MA
    Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
    Korzenik JR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide in refractory vulvar ulcerations associated with Crohn's disease.
    Kolivras A; De Maubeuge J; André J; Song M
    Dermatology; 2003; 206(4):381-3. PubMed ID: 12771492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.
    Akobeng AK; Stokkers PC
    Cochrane Database Syst Rev; 2009 Apr; 2009(2):CD007351. PubMed ID: 19370685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
    Bauditz J; Wedel S; Lochs H
    Gut; 2002 Feb; 50(2):196-200. PubMed ID: 11788559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
    Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB
    Gastroenterology; 1999 Dec; 117(6):1271-7. PubMed ID: 10579967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-alpha antagonists for the treatment of Crohn's disease.
    Kam LY; Targan SR
    Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104.
    Cohen LB
    Can J Gastroenterol; 2004 Jun; 18(6):419; author reply 419. PubMed ID: 15230268
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
    Ng SC; Plamondon S; Gupta A; Burling D; Swatton A; Vaizey CJ; Kamm MA
    Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.